Low doses of dexamethasone constantly delivered by autologous erythrocytes slow the progression of lung disease in cystic fibrosis patients

Blood Cells, Molecules, and Diseases

Volumn 33, Issue 1, 2004, Pages 57-63

  Rossi, Luigia ^a   Castro, Massimo ^b   D'Orio, Francesco ^b   Damonte, Gianluca ^c   Serafini, Sonja ^a   Bigi, Leonardo ^d   Panzani, Ivo ^d   Novelli, Giuseppe ^e   Dallapiccola, Bruno ^f   Panunzi, Simona ^g   Di Carlo, Pierluigi ^b   Bella, Sergio ^b   Magnani, Mauro ^a  

^a UNIVERSITY OF URBINO   (Italy)

^b BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d DIDECO SpA   (Italy)

^e UNIVERSITY OF ROME TOR VERGATA   (Italy)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

^g CNR   (Italy)

Author keywords

"Red Cell Loader"; Drug loaded erythrocytes; Glucocorticoid analogue; Inflammation; Pulmonary expiratory function

Indexed keywords

DEXAMETHASONE SODIUM PHOSPHATE;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTINUOUS PROCESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CYSTIC FIBROSIS; DISEASE COURSE; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; ENCAPSULATION; ERYTHROCYTE; FORCED EXPIRATORY VOLUME; GRAM NEGATIVE INFECTION; HUMAN; LOW DRUG DOSE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RECURRENT DISEASE; REPRODUCIBILITY; RESPIRATORY TRACT INFECTION; SCHOOL CHILD; SIDE EFFECT; SLOW RELEASE FORMULATION;

ADOLESCENT; ADULT; BLOOD TRANSFUSION, AUTOLOGOUS; CHILD; CYSTIC FIBROSIS; DEXAMETHASONE; DISEASE PROGRESSION; ERYTHROCYTE TRANSFUSION; ERYTHROCYTES; HUMANS; LUNG DISEASES; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RECURRENCE; TREATMENT OUTCOME;

PSEUDOMONAS; PSEUDOMONAS AERUGINOSA;

EID: 3042615711     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcmd.2004.04.004     Document Type: Article

References (22)

1. Davis P.B., Drumm M., Konstan M.W. Cystic fibrosis: state of the art. Am. J. Respir. Crit. Care Med. 154:1996;1229-1256
2. Konstan M.W., Berger M. Cystic Fibrosis. 1993;Marcel Dekker, New York
3. Konstan M.W., Berger M. Current understanding of the inflammatory process in cystic fibrosis: onset and etiology. Pediatr. Pulmonol. 24:1997;137-142
4. Price J.F., Greally P. Corticosteroid treatment in cystic fibrosis. Arch. Dis. Child. 68:1993;719-721
5. Rosenstein B.J., Eigen H. Risks of alternate-days prednisone in patients with cystic fibrosis. Pediatrics. 87:1991;245-246
6. Eigen H., Rosenstein B.J. A multicenter study of alternate day prednisone in patients with cystic fibrosis. J. Pediatr. 126:1995;515-523
7. Cheng K., Ashby D., Smyth R. Oral steroids for cystic fibrosis. Cochrane Database Syst. Rev. 2:2000;1-19. (CD000407)
8. Ihler G.M., Glew R., Schnure F. Enzyme loading of erythrocytes. Proc. Natl. Acad. Sci. U. S. A. 70:1973;2663-2666
9. Ropars C., Teisseire B., Avenard G., Chassaigne M., Hurel C., Girot R., Nicolau C. Improved oxygen delivery to tissues and iron chelator transport through the use of lysed and resealed red blood cells: a new perspective on Cooley's anemia therapy. Ann. N. Y. Acad. Sci. 445:1985;304-315
10. De Flora A., Zocchi E., Guida L., Polvani C., Benatti U. Conversion of encapsulated 5-fluoro-2′-deoxyuridine 5′-monophosphate to the antineoplastic drug 5-fluoro-2′-deoxyuridine in human erythrocytes. Proc. Natl. Acad. Sci. U. S. A. 85:1988;3145-3149
11. Rossi L., Bianchi M., Magnani M. Increased glucose metabolism by enzyme-loaded erythrocytes in vitro and in vivo normalization of hyperglycemia in diabetic mice. Biotechnol. Appl. Biochem. 15:1992;207-216
12. Magnani M., Fazi A., Mangani F., Rossi L., Mancini U. Methanol detoxification by enzyme-loaded erythrocytes. Biotechnol. Appl. Biochem. 18:1993;217-226
13. Magnani M., Giovine M., Fraternale A., Damonte G., Rossi L., Scarfì S., Benatti U., De Flora A. Red blood cells as a delivery system for AZT. Drug Delivery. 2:1995;57-61
14. Rossi L., Brandi G., Schiavano G.F., Scarfì S., Millo E., Damonte G., Benatti U., De Flora A., Magnani M. Heterodimer-loaded erythrocytes as bioreactors for slow delivery of the antiviral drug azidothymidine and the antimycobacterial drug ethambutol. AIDS Res. Hum. Retroviruses. 15:1999;345-353
15. D'Ascenzo M., Antonelli A., Chiarantini L., Mancini U., Magnani M. Red blood cells as a glucocorticoids delivery system. Sprandel U., Way J.L. Erythrocytes as Drug Carriers in Medicine. 1997;81-88 Plenum, New York
16. Magnani M., Rossi L., D'Ascenzo M., Panzani I., Bigi L., Zanella A. Erythrocyte engineering for drug delivery and targeting. Biotechnol. Appl. Biochem. 28:1998;1-6
17. Rossi L., Serafini S., Cenerini L., Picardi F., Bigi L., Panzani I., Magnani M. Erythrocyte-mediated delivery of dexamethasone in patients with chronic obstructive pulmonary disease. Biotechnol. Appl. Biochem. 33:2001;85-89
18. Zielenski J. Genotype and phenotype in cystic fibrosis. Respiration. 67:2000;117-133
19. Sangiuolo F., D'Apice M.R., Bruscia E., Lucidi V., Novelli G. Towards the pharmacogenomics of cystic fibrosis. Pharmacogenomics. 3:2002;75-87
20. Schleimer R.P. Effects of glucocorticosteroids on inflammatory cells relevant to their therapeutic applications in asthma. Am. Rev. Respir. Dis. 141:1990;S59-S69
21. Anene O., Meert K.L., Uy H., Simpson P., Sarnaik A.P. Dexamethasone for the prevention of postextubation airway obstruction: a prospective, randomized, double-blind, placebo-controlled trial. Crit. Care Med. 24:1996;1666-1669
22. Kai H., Yoshitake K., Hisatsune A., Kido T., Isohama Y., Takahama K., Miyata T. Dexamethasone suppresses mucus production and MUC-2 and MUC-5AC gene expression by NCI-H292 cells. Am. J. Physiol. 271:1996;L484-L488